Evidence map›Paper›PMID 30882323›Full record

ArticleEmerging infectious diseases2019

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.

Yacine Abed, Clément Fage, Patrick Lagüe, Julie Carbonneau, Jesse Papenburg, Donald C Vinh, Guy Boivin

Abstract readCase ReportsLetter
In one paragraph

Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yacine Abed
Clément Fage
Patrick Lagüe
Julie Carbonneau
Jesse Papenburg
Donald C Vinh
Guy Boivin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.

Indexed as

Drug Resistance, ViralAntiviral AgentsCanadaDose-Response Relationship, DrugEnzyme InhibitorsFemaleHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza B virusInfluenza, HumanMicrobial Sensitivity TestsMiddle AgedMutationNeuraminidaseSequence Analysis, DNAViral ProteinsAntiviral AgentsEnzyme InhibitorsHemagglutinin Glycoproteins, Influenza VirusNA protein, influenza B virusNeuraminidaseViral ProteinsCanadaGly407Serinfluenzainfluenza Bneuraminidaseoseltamivirperamivirresistanceviruseszanamivir

Identifiers

PMID30882323
PMCPMC6433030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.